Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without AIM chemotherapy in high-risk resectable soft-tissue sarcoma
NCT07823491Phase 3Not yet recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, ifosfamide in soft tissue sarcoma (STS), Liposarcoma, undifferentiated pleomorphic sarcoma (UPS), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)Liposarcomaundifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT07823491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823491.